Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Takeda Pharmaceutical Co ( (JP:4502) ) is now available.
Takeda and Protagonist Therapeutics announced the full 32-week results of their Phase 3 VERIFY study on rusfertide, presented at the ASCO Annual Meeting. The study, which targeted patients with polycythemia vera, successfully met its primary and secondary endpoints, demonstrating significant reductions in phlebotomy and improved hematocrit control. Despite the positive clinical outcomes, the impact on Takeda’s financial results for FY2025 is expected to be minimal.
The most recent analyst rating on (JP:4502) stock is a Buy with a Yen5500.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
More about Takeda Pharmaceutical Co
Takeda Pharmaceutical Co is a global pharmaceutical company based in Japan, focusing on the development of innovative medicines. The company operates in various therapeutic areas, including oncology, gastroenterology, neuroscience, and rare diseases.
YTD Price Performance: 5.44%
Average Trading Volume: 5,309,542
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen6837.5B
Learn more about 4502 stock on TipRanks’ Stock Analysis page.